- Home
- MRCC vs NYXH Comparison
MRCC vs NYXH Comparison
Compare MRCC & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRCC
- NYXH
- Stock Information
- Founded
- MRCC 2011
- NYXH 2009
- Country
- MRCC United States
- NYXH Belgium
- Employees
- MRCC N/A
- NYXH 184
- Industry
- MRCC Investment Managers
- NYXH Medical/Dental Instruments
- Sector
- MRCC Finance
- NYXH Health Care
- Exchange
- MRCC Nasdaq
- NYXH Nasdaq
- Market Cap
- MRCC 155.1M
- NYXH 179.1M
- IPO Year
- MRCC 2012
- NYXH 2021
- Fundamental
- Price
- MRCC $7.57
- NYXH $4.65
- Analyst Decision
- MRCC Hold
- NYXH Strong Buy
- Analyst Count
- MRCC 1
- NYXH 3
- Target Price
- MRCC $8.00
- NYXH $15.00
- AVG Volume (30 Days)
- MRCC 72.2K
- NYXH 73.9K
- Earning Date
- MRCC 11-11-2025
- NYXH 11-05-2025
- Dividend Yield
- MRCC 13.28%
- NYXH N/A
- EPS Growth
- MRCC N/A
- NYXH N/A
- EPS
- MRCC 0.09
- NYXH N/A
- Revenue
- MRCC $51,229,000.00
- NYXH $5,793,306.00
- Revenue This Year
- MRCC N/A
- NYXH $118.20
- Revenue Next Year
- MRCC N/A
- NYXH $278.04
- P/E Ratio
- MRCC $85.24
- NYXH N/A
- Revenue Growth
- MRCC N/A
- NYXH 2.94
- 52 Week Low
- MRCC $5.96
- NYXH $4.57
- 52 Week High
- MRCC $8.85
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- MRCC 72.81
- NYXH 21.90
- Support Level
- MRCC $7.41
- NYXH $5.45
- Resistance Level
- MRCC $7.65
- NYXH $6.09
- Average True Range (ATR)
- MRCC 0.12
- NYXH 0.28
- MACD
- MRCC -0.02
- NYXH -0.09
- Stochastic Oscillator
- MRCC 72.73
- NYXH 4.72
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.